The Food and Drug Administration said 561 deaths are reportedly tied to recalled sleep apnea devices made by Philips Respironics. This comes as Philips Respironics this week agreed to stop selling new ...

The move comes as Philips has agreed to a consent decree with the Food and Drug Administration and the Department of Justice that could cost the company nearly $400 million. In June 2021, Philips ...

The FDA has received more than 500 reports of death tied to Philips’ recalled sleep apnea devices since 2021, according to a Jan. 31 agency update. The devicemaker recalled millions of ventilators and ...

National Council on Aging statistics indicate an estimated 39 million U.S. adults have obstructive sleep apnea, while 936 million adults around the world are estimated to have mild to severe OSA.

Shares of medical giant Philips surged Monday after the company announced that it paid over a billion dollars to settle personal injury claims tied to its recalled sleep apnea devices. Philips ...

This article originally appeared on ProPublica. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.

Philips, a leading maker of CPAP machines, has agreed to pay $1.1 billion to settle lawsuits over faulty sleep apnea devices. The company said more than 58,000 people have already registered for the ...

HONOLULU (KHON2) — The Federal Drug Administration recalled hundreds of Philips ventilators, bilevel positive airway pressure machines, and continuous positive airway pressure machines in June 2021.

Medical device maker Philips said Monday it will pay $1.1 billion to settle hundreds of personal injury lawsuits in the U.S. over its defective sleep apnea machines, which have been subject to a ...

Add Yahoo as a preferred source to see more of our stories on Google. Inspire Sleep Apnea Innovation Around 22 million Americans have sleep apnea. Traditional continuous positive airway pressure, or ...

Breathing machines with adaptive servo-ventilation (ASV) did not improve survival or other clinical outcomes in patients with heart failure (HF) and reduced ejection fraction and sleep-disordered ...